Breaking News
June 24, 2018 - CytoReason builds largest reference of immune-focused inter-cellular communications
June 24, 2018 - Enlist a Pharmacist to Help Manage High Blood Pressure
June 24, 2018 - Genes found related to the reduction of proteins that contribute to Alzheimer’s onset
June 24, 2018 - 1 in 5 immigrant children detained during ‘zero tolerance’ border policy are under 13
June 24, 2018 - Personal automated cell lab assistant from Leica saves time with quality results
June 24, 2018 - Drug use can have social benefits, and acknowledging this could improve rehabilitation
June 24, 2018 - AMSBIO introduces MyEZGel 3D-iPSC Matrix for more accurate in vivo predictions
June 24, 2018 - RaySearch releases new RayStation 8A to expand support for TomoTherapy platform
June 24, 2018 - Dying cancer cells make remaining glioblastoma cells more aggressive and therapy-resistant
June 24, 2018 - Researchers discover new type of cell that hinders formation of fat cells
June 24, 2018 - Scientists develop unique program to predict a form of Parkinson’s disease
June 24, 2018 - Adult Obesity Prevalence Varies With Level of Urbanization
June 24, 2018 - Picking an exercise boot camp
June 24, 2018 - Researchers outline a connection between subplate neurons and brain disorders
June 24, 2018 - Four cups of coffee a day shown to protect heart muscle
June 24, 2018 - ‘Antifreeze’ molecules may hold key to better treatments for brain injuries
June 24, 2018 - Opening onsite health clinics for workers can cut health care costs
June 24, 2018 - Glooko to demonstrate new version of diabetes management mobile application at ADA meeting
June 24, 2018 - Florida Teen First Human Case of Another Mosquito-Borne Virus
June 24, 2018 - Blood type O patients may have higher risk of death from severe trauma
June 24, 2018 - New studies on molecular and cellular proteomics
June 24, 2018 - Algorithm predicts dangerous low blood pressure during surgery
June 24, 2018 - Herpes may play role in pathogenesis of Alzheimer’s
June 24, 2018 - Inaccurate measurement of sodium intake may account for paradoxical results, study suggests
June 24, 2018 - Aquinnah Pharmaceuticals wins NINDS grant to advance novel therapies for ALS
June 24, 2018 - Study upends conventional view of opioid mechanism of action
June 24, 2018 - Floppy eyelids may be sign of sleep apnea, study finds
June 23, 2018 - Researchers highlight new nurse training model to address shortage of primary care
June 23, 2018 - New Olympus cellSens 2.1 speeds up image analysis
June 23, 2018 - Attitudes Among Obese Are Not Aligned With Healthy Living
June 23, 2018 - Early birds less prone to depression
June 23, 2018 - Scientists use novel approach to uncover how brain networks interact to make word-choice decisions
June 23, 2018 - Researchers discover shared genetic basis for psychiatric disorders
June 23, 2018 - Study shows fat cells increase in size and number upon exposure to fracking chemicals
June 23, 2018 - Water-limited landscapes can facilitate disease transmission
June 23, 2018 - Exercise May Ease Inflammation Tied to Obesity
June 23, 2018 - Is it their own fault?! How people judge the exclusion of others
June 23, 2018 - Researchers use advanced technology to identify proteomes of Th17 and iTreg cells
June 23, 2018 - Researchers develop low-cost plastic sensors to monitor wide range of health conditions
June 23, 2018 - Lipid-scrambling DNA enzyme outperforms naturally occurring counterpart, say researchers
June 23, 2018 - Apps for children should emphasize parent and child choice, researchers say
June 23, 2018 - Teenage girls report higher degree of daytime sleepiness than boys
June 23, 2018 - Protein Data Bank at Rutgers impacts research, education and drug discovery
June 23, 2018 - Study unravels new piece of information in the Huntington’s disease puzzle
June 23, 2018 - Scientists develop new device to test cancer drug combinations quickly and cheaply
June 23, 2018 - Neural Analytics wins CE Mark for NeuralBot System
June 23, 2018 - Infant omega-3 supplementation tied to decreased waist size
June 23, 2018 - Massive analysis of genomes reveals insights into genetic overlap among psychiatric diseases
June 23, 2018 - New therapeutic approach may delay neurodegeneration in rare genetic disease
June 23, 2018 - Broken shuttle protein may hinder learning in patients with brain disorders
June 23, 2018 - Study finds increase in daily cannabis use among American adults
June 23, 2018 - Researchers create electronic skin that brings back real sense of touch to prosthetic limbs
June 23, 2018 - FIRS: Guidance Offered for Protecting Youth From E-Cigarettes
June 23, 2018 - Scientists unravel molecular mechanisms of Parkinson’s disease
June 23, 2018 - When the Heart Stops, Drugs Often to Blame
June 23, 2018 - Scientists show that a key Parkinson’s biomarker can be identified in the retina
June 23, 2018 - Study finds factors underlying current rise in radicalization among European youth
June 23, 2018 - New study finds higher heart disease risk in bisexual men
June 23, 2018 - Coconut oil diet increases vitality, lifespan of fruit flies with peroxisomal disorder
June 23, 2018 - Jumping genes or transposons and their role in the genetic code
June 23, 2018 - The Current issue of “The view from here” is concerned with Therapeutics
June 23, 2018 - Abnormal lipid metabolism in fat cells predicts future weight gain and diabetes in women
June 23, 2018 - Alcohol problems linked to sex without condom use among black gay men
June 23, 2018 - DNA patterns in circulating blood cells can help identify spastic cerebral palsy
June 23, 2018 - Unsubstantiated health claims widespread within weight loss industry
June 23, 2018 - FDA grants marketing authorization for use of two catheter-based devices in hemodialysis patients
June 23, 2018 - An ingrown toenail not the same as a bypass
June 23, 2018 - Study suggests proteinuria lowering as important target in managing pediatric CKD
June 23, 2018 - Dynamic model helps make predictions about gut microbiome
June 23, 2018 - Research consortium wins £2.9 million to help tackle antibacterial resistance in Thailand
June 23, 2018 - Schizophrenia patients account for over 1 in 10 suicide deaths, study shows
June 23, 2018 - Overdose risk increases five-fold with concurrent opioid and benzodiazepine use
June 23, 2018 - FDA Alert: Kratom (mitragyna speciosa) powder products by Gaia Ethnobotanical: Recall
June 23, 2018 - Study highlights inadequate effort of health care insurers to combat opioid epidemic
June 23, 2018 - CDC chief asks for, and gets, cut to his record $375K pay
June 22, 2018 - Novel cellular pathway may clarify how arterial inflammation develops into atherosclerosis
June 22, 2018 - Pioneering exercise program improves physical, mental health of elderly people living in care homes
June 22, 2018 - Rutgers Cancer Institute educates childhood cancer survivors about late effects of treatment
June 22, 2018 - Study tests accuracy of device designed to detect heart dysfunction in childhood cancer survivors
June 22, 2018 - Study links annual haze with increased hospitalizations for respiratory problems
FDA Approves Apalutamide (Erleada) to Help Curb a Tough-to-Treat Prostate Cancer

FDA Approves Apalutamide (Erleada) to Help Curb a Tough-to-Treat Prostate Cancer

image_pdfDownload PDFimage_print

WEDNESDAY, Feb. 14, 2018 — A new drug that can stall the progression of a particularly hard-to-treat form of prostate cancer has been approved for use by U.S. health officials.

In a recent study, the drug called Erleada (apalutamide) has shown breakthrough effectiveness in keeping prostate cancer from spreading for two years in men whose disease had not yet traveled to other parts of their body.

After the drug was granted Priority Review by the U.S. Food and Drug Administration, the agency announced Wednesday that it had approved Erleada “for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy.”

A second, already approved drug, Xtandi (enzalutamide), has also shown similar effectiveness against these types of prostate cancer cases.

Dr. Matthew Smith was primary researcher of the Erleada trial that helped lead to the new approval. His team published its results Feb. 8 in the New England Journal of Medicine.

Smith explained that men newly diagnosed with prostate cancer that hasn’t spread are first treated with androgen-deprivation therapy — a medication that robs the tumor of the testosterone that helps fuel its growth.

This strategy “always works, and [then] it almost always stops working,” said Smith, who directs the genitourinary malignancies program at Massachusetts General Hospital in Boston.

“And when it stops working, that’s what we call castration-resistant prostate cancer,” he explained.

Until now, there have been no approved treatments for prostate cancer at that stage, Smith said. The men are simply put under observation until their cancer migrates, at which point treatment resumes.

Tens of thousands of men in the United States are estimated to be in this situation and they have a very poor prognosis, particularly if their levels of prostate-specific antigen (PSA) are rapidly rising, Smith said. PSA is a protein produced by the prostate gland; a sudden elevation of PSA levels has been linked to increased prostate cancer risk.

“There’s an unmet need there,” Smith said. “Their expected survival is similar to that of men with newly diagnosed prostate cancer that has already spread to bone.”

Both Erleada and Xtandi battle prostate cancer by binding to the androgen receptor on tumor cells, blocking its activation by testosterone and other male hormones, explained Dr. Oliver Sartor, medical director of the Tulane Cancer Center in New Orleans. He co-wrote a commentary accompanying the apalutamide trial.

“Both the drugs are incredibly similar to one another,” Sartor said. “If you look at the chemical structure, they’re extremely close to one another. Mechanistically, they operate the same way.”

In the Erleada trial, Smith’s group tested the pill against a placebo.

The result: Erleada extended progression-free survival by about two years over a placebo, researchers found — 40.5 months versus 16.2 months. That means patients continued to live their lives without the disease progressing.

Men taking Erleada had a 72 percent lower risk of invasive cancer or death, based on results from more than 1,200 patients at 322 sites in 26 countries, the study found.

“It was a very big effect,” Smith said.

The FDA said that, in a first for cancer drugs, it based its approval of Erleada not on overall survival results, but on how long patients survived without their cancer spreading.

For his part, Smith said he expects Erleada to become the standard of care for men with this form of prostate cancer.

But other experts think Xtandi could steal the new drug’s thunder.

Dr. Alexander Kutikov, chief of urologic oncology with Fox Chase Cancer Center in Philadelphia, noted that Xtandi demonstrated similar results in studies, and it’s already in use as a prostate cancer therapy.

“I suspect barriers to its use, at least initially, will be much lower than to that of apalutamide [Erleada],” he said.

Sartor agreed. “I think [Erleada] will become a standard of care. I hesitate to think it will be the standard of care,” he said.

And he noted that both drugs come with significant side effects — most commonly rash and increased risk of fracture — and men not suffering any symptoms might not want to take the risk of drug-related adverse events.

For example, rash occurred in almost 24 percent of men taking Erleada versus 5.5 percent in the placebo group. And fractures occurred in close to 12 percent of Erleada users, versus 6.5 percent in the placebo group. However, only about 10 percent of men taking the cancer drug dropped out due to side effects, compared with 7 percent and 8 percent of the placebo groups.

The Erleada trial was paid for by Johnson & Johnson.

More information

For more on prostate cancer, visit the U.S. National Cancer Institute.

© 2018 HealthDay. All rights reserved.

Posted: February 2018

Tagged with:

About author

Related Articles